Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been studied for their cardiovascular benefits in type 2 diabetes. Here, the authors show that GLP-1 RAs are associated with reduced mortality and improved cardio-renal outcomes in type 2 diabetes patients with acute kidney disease.
- Heng-Chih Pan
- Jui-Yi Chen
- Vin-Cent Wu
